real-time news and commentary for investors
Tuesday, Apr 16
Acorda Therapeutics (ACOR +11.2%) rises for a second day after AMPYRA shows promise for...
Acorda Therapeutics (ACOR +11.2%) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call: 1) "What got us here [is] an adherence to analysis in science [and] we're not going to deviate from that" just to get into a Phase III trial. 2) An 18-20% improvement in the timed 25-foot walk speed "correlates very well with various measures of clinically meaningful improvement," but the comparison between the current study and the MS study "is not apples-to-apples."